Publications by authors named "Matthias Lutterbeck"
Article Synopsis
- Establishing effective treatments for high-risk COVID-19 patients, particularly those with weakened immune systems or pre-existing conditions, is difficult due to limited options and insufficient data on therapies like convalescent plasma (CP).
- A study analyzed 55 hospitalized patients at risk for severe disease compared to a larger group of 220 matched patients, finding no significant difference in mortality rates between those treated with CP and those who weren't.
- The analysis suggested that early CP administration, before severe lung complications develop, may reduce mortality rates, while treatment during critical illness resulted in much higher death rates.
Background: COVID-19, the pandemic disease caused by infection with SARS-CoV-2, may take highly variable clinical courses, ranging from symptom-free and pauci-symptomatic to fatal disease. The goal of the current study was to assess the association of COVID-19 clinical courses controlled by patients' adaptive immune responses without progression to severe disease with patients' Human Leukocyte Antigen (HLA) genetics, AB0 blood group antigens, and the presence or absence of near-loss-of-function delta 32 deletion mutant of the C-C chemokine receptor type 5 (CCR5).
Patient And Methods: An exploratory observational study including 157 adult COVID-19 convalescent patients was performed with a median follow-up of 250 days.
Background: Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g.
View Article and Find Full Text PDFBackground: Patients in palliative care need rapid-acting pharmacological options for psychological distress. N-methyl-D-aspartate antagonist ketamine is known to have a fast onset of anti-depressant and anxiolytic action. Its S-enantiomer S-ketamine (or esketamine) is an analgesic used as a routine treatment for refractory pain as an intravenous infusion (0.
View Article and Find Full Text PDFThe role of the NH(3) ligands in the highly successful antitumour agents cisplatin and carboplatin is not fully understood. Suggestions that the ammonia ligands are involved in target recognition through hydrogen bond formation, e.g.
View Article and Find Full Text PDF